Schizophrenia and Psychoses Archive
Remission can be achieved for most cases of schizophrenia and schizophreniform disorder with amisulpride and clozapine.
The dose-response relationship observed between CBT and schizophrenia outcome may be salient to clinicians in titrating treatment strategies.
There was a significantly higher level of prolactin found in the first episode psychosis group than in the clinical high risk group, suggesting a condition of hyperprolactinemia.
Researchers found a suicide attempt rate of 12.0% in first-episode, drug-naive inpatients.
The findings support second generation long-acting injectable antipsychotic drug use as early treatment option to increase treatment adherence and to decrease the risk of relapse, hospitalization, and deteriorating social functions.
WSE treatment may be useful in addressing symptom exacerbation in schizophrenia and schizoaffective disorder.
Investigators examined factors that may improve employment in patients with schizophrenia.
Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.
These results may be helpful for clinicians when considering the effects of antipsychotic intervention on patient high-density lipoprotein cholesterol levels.
Inhalant and other substance use during adolescence are increasingly associated with many adverse health and psychosocial outcomes.
These data have implications for the efficacy of the US military healthcare system as a whole in treating psychosis in service members.
As psychosis and substance use disorder comorbidity can make oral medication adherence difficult, long-acting injectable agents may be an effective therapeutic alternative in patients in this demographic.
Each of the studied brain modalities could be classified as "gray matter abnormalities" or "white matter disruptions" and may be significant in the pathology of schizophrenia.
This study created a validated model for determining brain age and brain age gap, which then can be used to predict early-onset psychosis in younger clinically high-risk adolescents who exhibit prodromal symptoms.
The findings of this study contribute to the understanding of the neurodevelopmental cognitive vulnerability in middle childhood for the children of people with either schizophrenia or bipolar disorder.
These data suggest that aripiprazole can be safely used in premenopausal women to treat elevated prolactin levels and prolactin-related adverse effects.
Atypical antipsychotic use was associated with a higher risk for cardiovascular events among publicly insured youth in the US.
Prior to this approval, the Aristada initiation regimen consisted of taking oral aripiprazole for 21 consecutive days starting with the first Aristada dose.
Results of this meta-analysis highlight the potential advantages of long-acting injectable antipsychotics vs oral antipsychotics in treating schizophrenia.
In considering patients with schizophrenia for cognitive remediation, comorbid OCD must be taken into account.
These results indicate that impaired visual integration in patients with schizophrenia may more broadly be a feature of psychosis, rather than specifically of schizophrenia.
Researchers hope that in demonstrating the potential efficacy of MIN-101, they may improve the pharmacotherapy options available to patients with schizophrenia.
The superior benefit provided by early intervention services for schizophrenia could be cost-effective, and the researchers call for widespread implementation and funding of early intervention services in the United States and globally.
To date, there has been limited prognostic accuracy of clinical instruments in predicting the onset of psychosis and no reliable biological marker has been identified.
Researchers conducted a systematic literature review to identify cohort studies reporting the standardized incidence ratio for the risk of breast cancer in women with schizophrenia compared with the general population.
These data may be helpful in titrating care for those with schizotypal disorder and comorbid substance abuse disorders to mitigate the risk for conversion to schizophrenia.
Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.
These findings may be helpful in developing treatment strategies for patients with past trauma and sleep disturbances to attenuate the possibility of future psychosis-like experiences.
The authors advised clinicians to carefully consider which antipsychotics they prescribe their patients with metabolic dysfunction, as some are known to be diabetogenic.
These data may be useful to clinicians in considering the risks and benefits of prescribing haloperidol for patients with cardiac morbidity.
In patients with a history of pre-diagnostic violence, a history of non-violent offending in the 18-month period pre-diagnosis was the strongest predictor of future violence.
The authors pointed to a possible difference in the specific symptoms alleviated by different types of stimulation.
The early sustained recovery group was more likely to have a diagnosis other than schizophrenia, particularly mania or brief psychosis.
Although various clinical and psychosocial factors were associated with unhealthy lifestyle factors and higher risk for CVD, the strongest associations were with negative symptoms.
Treatment beyond antipsychotic drugs is needed for people with schizophrenia, as positive symptoms are a peripheral node in the network.
Given the high risk for metabolic disorder and type 2 diabetes, clinicians should select psychotropic medications carefully and monitor metabolic conditions regularly in their patients with serious mental illness.
Despite the recognition that early daily tobacco use likely increases the risk for later psychosis, investigation of the effect of covariates such as substance use, existing psychotic features, or parental/family factors was lacking in the literature.
These results suggest that CBT alone may be insufficient in enhancing work outcomes in patients with schizophrenia, despite its efficacy in treating other symptoms.
The meta-analysis showed raloxifene to be effective for positive symptoms, negative symptoms, and general psychopathology, with greatly homogeneous results.
The findings of this meta-analysis suggested that both repetitive transcranial magnetic stimulation and transcranial direct current stimulation were significantly more effective at improving negative symptoms than sham stimulation.
Investigators determined infections in the first year of life to be the "sensitive period" for risk of adult nonaffective psychosis.
Children who are involved in sibling bullying are at a higher risk of developing a psychotic disorder.
Investigators selected 15 genes associated with schizophrenia due to high expression in both brain tissue and B-lymphocyte cells.
There has been a question of whether antipsychotic medications are truly acting upon "primary" negative symptoms, or whether they are instead improving "secondary" negative symptoms via improvement in positive or depressive symptoms.
Although all-cause pharmacy costs were higher in the paliperidone palmitate group, adjusted all-cause medical costs were lower.
Use of virtual reality environments in which participants interact with computer-controlled situations or avatars enables a more fine-tuned approach to exposure in the context of cognitive behavioral therapy.
A combination of an SSRI and antipsychotics in a clinical setting most likely does not lead to a further deterioration of metabolic variables to a clinically significant degree.
tDCS may be an important tool for further improving our understanding of psychosis and designing targeted treatments.
Researchers examined which atypical antipsychotic was more effective and safe in first-episode drug-naive schizophrenia.
A meta-analysis of randomized, controlled trials compared the use of benzodiazepines alone or in combination with antipsychotic or antihistamine medications in patients experiencing acute psychotic illness.
Investigators seek the association between psychosis and complication risk after total joint arthroplasty.
P50 processing may inform researchers in the future development of interventions targeting cognitive impairment in schizophrenia.
All patients with a substance-induced psychosis should be offered follow-up.
This research suggests that interventions to improve cognitive insight may bolster neurocognition in schizophrenia.
Investigators seek the association between the risk of developing schizophrenia and advanced maternal and paternal age.
Gender differences may predict the types of symptoms and age of onset of schizophrenic psychosis.
Investigators assessed biomarkers for cardiovascular risk and protection in individuals with first-episode psychosis.
Investigators believe social recovery therapy may benefit individuals with complex comorbidities not motivated to participate in psychosocial interventions targeting functioning after first-episode psychosis.
Twelve antipsychotics, including olanzapine, ziprasidone, and lurasidone, were examined in a meta-analysis.
Technique validation suggested a robust generalizability of neuroanatomical imaging in schizophrenia.
AVATAR therapy significantly reduced the severity of hallucinations compared with supportive counseling.
A schizophrenia-related polygenic-risk score association gradient was identified across bipolar disorder phenotypes.
The severity of psychotic symptoms in patients with bipolar affective disorder correlated inversely with the response to lithium therapy.
Patients with schizophrenia-spectrum disorders had higher odds of being aggressive than people with bipolar disorder with a recent manic episode.
For patients with schizophrenia or schizoaffective disorder, younger age was significantly associated with an increased rate of readmission.
The ability to track ingestion of medications prescribed for mental illness may be useful for some patients.
The risk of developing schizophrenia may be impacted by specific inflammatory biomarkers.
Transcranial direct current stimulation might aid patients with schizophrenia who experience auditory hallucinations.
Lurasidone reduced agitation in patients with acute exacerbation of schizophrenia.
People with schizophrenia have a mortality rate 3 times higher than the general population, which may be linked to higher rates of smoking, alcohol consumption, poor diet, and lack of exercise in people with schizophrenia.
The quality of diabetes care was examined in patients with and without schizophrenia in a Danish nationwide cohort.
In patients with schizophrenia, long-acting injectable formulations of paliperidone palmitate delay relapse significantly after withdrawal.
Dopamine dysfunction underlies the pathoetiology of psychosis in both bipolar disorder and schizophrenia.
Researchers conducted a prospective case-control study to examine predictors of early and late-onset psychosis in Parkinson disease.
These findings suggest that there are critical periods of development associated with a higher risk of persistent negative symptoms.
In this study, 672 patients with schizophrenia were evaluated with the EPICOG-SCH brief cognitive battery.
Seven signs and symptoms might alert someone to the possible presentation of schizophrenia.
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
The FDA issued a refusal to file letter for a new drug application.
Switching therapy to Aristada resulted in statistically significant and clinically meaningful improvement in schizophrenia symptoms.
Adding telmisartan to treatment with olanzapine or clozapine may improve symptoms of schizophrenia.
Researchers from the University of Texas Southwestern Medical Center have discovered the cellular receptor that causes weight gain from antipsychotic drugs.
Long-term treatment of schizophrenia with cariprazine was found to be both safe and well-tolerated.
The FDA has approved Austedo.
Children and adolescent offspring of patients with schizophrenia demonstrate more attenuated psychotic symptoms.
Glucose tolerance and body mass index in patients with schizophrenia were improved by liraglutide.
Patients with schizophrenia in the MIN-101 trial demonstrated lower negative factor scores than a placebo group.
Impaired recollection could be a vulnerability marker for schizophrenia, whereas impaired social context memory could be a disease-related marker.
Schizophrenia treatment with long-acting injectable antipsychotic agents resulted in lower rehospitalization rates.
Clozapine-induced gastrointestinal hypomotility is a medical emergency that requires urgent attention.
A high percentage of patients were persistent and adherent to their PP3M treatment.
Clozapine might lower risk of self-harm for patients with treatment-resistant schizophrenia.
HIV, hepatitis B and hepatitis C are more common among patients with mental illnesses.
Interventions targeted at improving medication adherence might mitigate adverse effects of cannabis use on psychosis outcomes.
Long-acting injectables should be considered earlier in the treatment of schizophrenia.
Child maltreatment is significantly more prevalent in young individuals who present with UHR symptoms compared with controls.
Increases in autonomic function may predict the occurrence and severity of auditory hallucinations in patients with schizophrenia, suggesting a regulation of these experiences by the autonomic nervous system.
Diabetes mellitus (DM) appears to be more prevalent in the psychiatric setting than in the general population.
The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.
Schizophrenia patients may benefit from a a specific type of talk therapy, according to a new study from the University of Pennsylvania.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Link Identified Between Cured Meat and Mania in Bipolar Disorder
- First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes
- Early Risk Factors for Bipolar Disorder Found in Offspring of BD Parents
- Prevalence of Schizophrenia in Individuals With Type 2 Diabetes
- Daily Drinking Associated With Increased Mortality Risk
- The Opioid System: The Foundation for Social Risk and Reward
- Correctional Psychiatry: Challenges and Rewards
- Those Left Behind: Working With Suicide-Bereaved Families
- The Impact of Deafness on Hallucinations and Delusions
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Mental Health Problems in Adolescents With HIV: Overview & Expert Interview
- Should Physicians Play a Role in Minimizing the Societal Cost of Medical Care?
- Digital Cognitive Behavioral Therapy Effective for Individuals With Insomnia
- How Do Medical Scribes Reduce EHR Documentation Burden for Physicians?